Buffett's Prescription: Fixing a 95% Healthcare Heavy Portfolio

Pull up a chair and grab yourself a Cherry Coke. I was looking over your portfolio, and for a minute there, I thought I had accidentally opened a stack of Charlie Munger’s old medical bills! You've named this collection "Global Longevity & Innovation Alpha," which sounds exactly like the kind of fancy jargon a Wall Street salesman uses to justify charging you high fees.

I’ve always said that investing is not a game where the guy with the 160 IQ beats the guy with the 130 IQ. It's about rationality and temperament. You've clearly done some homework—you're buying real businesses with real revenues, which puts you miles ahead of the folks gambling on internet dog coins. But looking at how you've put this all together, I think we need to have a serious talk about the difference between finding a good business and building a resilient portfolio. Let's look under the hood.

When I look at your sector breakdown, I have to chuckle. Your healthcare exposure is practically sitting at 80%, and then your "Broad Market" slice is 15.5%. But what is that broad market slice? The Health Care Select Sector SPDR Fund (XLV). That means roughly 95% of your hard-earned money is betting entirely on people getting sick, getting old, or trying to lose weight!

You’ve got over 58% of your money aggressively chasing growth, largely fueled by Novo Nordisk and Eli Lilly, which together make up nearly a quarter of your holdings. Now, these are wonderful businesses with massive scale advantages. But as I always say, a wonderful company at a fair price beats a fair company at a wonderful price. You are paying a very steep premium for that growth.

Looking at your competitive moats, I see about 56% of your portfolio is protected by intangible assets, mostly patents. Patents are fine, but remember: a pharmaceutical patent eventually expires. The secret formula for Coca-Cola does not.

Finally, let's talk about your cash reserves. You are sitting at 5.1% cash. That's enough to keep the lights on and buy a few hamburgers at Dairy Queen, but it leaves you with a severe lack of dry powder. Cash is king only when you deploy it, but you need to have it when Mr. Market gets depressed and puts wonderful businesses on sale.

🚩 Extreme Sector Concentration: Diversification is protection against ignorance. Putting 95% of your net worth into a single sector isn't investing; it's practically running a pharmaceutical hedge fund. You are one major government healthcare regulation or FDA policy shift away from a portfolio-wide disaster.

🚩 Chasing the Diet Pill Trend: You've loaded up almost 24% of your money on the GLP-1 weight-loss craze through Novo Nordisk and Eli Lilly. They have incredible products, but the market knows that. When a trend is front-page news, the price usually reflects perfection. If their growth slows even slightly, the lack of a margin of safety will punish you.

🚩 Redundant "Diworsification": You hold 15.5% in the XLV ETF, presumably for broad exposure. But look at your individual stocks! You already own UnitedHealth, Johnson & Johnson, and Eli Lilly directly, which are the biggest holdings in that exact ETF. You are paying fund management fees just to buy the exact same stocks you already own.

I'll give this portfolio a 5.5 out of 10. You are buying high-quality, profitable businesses with real moats, which I love. But your portfolio construction needs major surgery before the market teaches you a painful lesson about concentration risk.

Here is my prescription:

1. Build your cash buffer: Bump that 5.1% cash reserve up a bit. You want your elephant gun loaded when the market eventually panics.

2. Step outside the hospital: Find wonderful businesses in other sectors—perhaps financials, consumer staples, or industrials—to balance out this massive healthcare bet.

3. Check your prices: Re-evaluate your growth stocks. Ensure you aren't paying tomorrow's perfect prices for today's good news. Insist on a margin of safety.

4. Clean up the overlap: Decide if you want to be a stock picker or an indexer in the healthcare space. Holding both the individual heavyweights and the sector ETF is inefficient.

As my old partner Charlie used to say, "The big money is not in the buying and the selling, but in the waiting." Make sure you are holding a portfolio you can actually afford to wait with.